"The new facility is a great addition to our well-established development and scale-up services, says the president of Cambrex's Biopharmaceutical Business Unit, Peter van Hoorn. "With the enhanced capabilities, a dedicated staff of professionals and a well-defined regulatory infrastructure, Cambrex Bio Science is well positioned to be the premier supplier of development and manufacturing services to in the biopharmaceutical industry. The capital investment fits well with our strategy to work with customers on projects early in the development process that feed into clinical and commercial production opportunities."
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to asset-and-logo-licensing@alm.com. For more inforrmation visit Asset & Logo Licensing.
